Stocks of cancer treatment developers will be moving into the spotlight later this week when the annual meeting of the ...

Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.